New Risk • Jul 28
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩142.5b (US$97.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (₩2.2b revenue, or US$1.5m). Market cap is less than US$100m (₩142.5b market cap, or US$97.6m). New Risk • Apr 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (₩2.6b revenue, or US$1.7m). Aankondiging • Mar 13
Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026 Helixmith Co., Ltd, Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 21, magokjungang 8-ro 7-gil, gangseo-gu, seoul South Korea New Risk • Sep 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Revenue is less than US$5m (₩5.0b revenue, or US$3.6m). New Risk • Aug 30
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (26% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.7% average weekly change). New Risk • Aug 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₩5.1b revenue, or US$3.7m). Aankondiging • Mar 13
Helixmith Co., Ltd, Annual General Meeting, Mar 27, 2025 Helixmith Co., Ltd, Annual General Meeting, Mar 27, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 21, magokjungang 8-ro 7-gil, gangseo-gu, seoul South Korea New Risk • Dec 07
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (₩127.3b market cap, or US$89.5m). New Risk • Nov 22
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩140.0b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (₩3.2b revenue, or US$2.3m). Market cap is less than US$100m (₩140.0b market cap, or US$99.9m). Aankondiging • Apr 26
Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in funding On April 25, 2024, Helixmith Co., Ltd closed the transaction. Aankondiging • Feb 06
Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in funding Helixmith Co., Ltd announced a private placement of 936,066 common shares at a price of KRW 3,610 per share for the gross proceeds of KRW 3,379,198,260 on February 5, 2024. The transaction has been approved by the shareholders of the company and is expected to close on April 25, 2024. The transaction will include participation from new investor, Woori Bank Magongnaru Station Branch. New Risk • Dec 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Revenue is less than US$5m (₩4.4b revenue, or US$3.4m). Aankondiging • Feb 09
Helixmith Co., Ltd announced that it expects to receive KRW 9.999993078 billion in funding from CANARIABIO M Inc. Helixmith Co., Ltd announced a private placement of 936,066 common shares of par value KRW 500 to be issued at an issue price of KRW 10,683 per share for proceeds of KRW 9,999,993,078 on February 7, 2023. The transaction will include participation from returning investor CANARIABIO M Inc. The shares are to be issued pursuant to third party allotment method. The transaction is expected to close on February 15, 2023. The transaction has been approved by the board of directors. The securities will be subject to a hold period of one year. Price Target Changed • Nov 29
Price target decreased to ₩19,900 Down from ₩29,600, the current price target is provided by 1 analyst. New target price is 51% above last closing price of ₩13,150. Stock is down 41% over the past year. The company posted a net loss per share of ₩1,753 last year. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Aankondiging • Sep 19
Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD) Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD) Aankondiging • Sep 07
Helixmith Announces Topline Results from Phase 2A Study of Engensis for Treatment of ALS (Amyotrophic Lateral Sclerosis) Helixmith announced topline results from a Phase 2A study in individuals with ALS (Amyotrophic Lateral Sclerosis). ALS is a fatal neurodegenerative disorder of upper and lower motor neurons that causes progressive paralysis and eventual death due to respiratory failure. This Phase 2A was a double-blind placebo controlled multi-center study involving 5 sites (4 in the US and 1 in Korea) and 18 subjects randomized to a 2:1 ratio of Engensis to placebo. In this Phase 2A study, three treatments of Engensis, a plasmid DNA encoding human HGF, or placebo were injected in the upper and lower limbs on months 0, 2 and 4. One treatment consisted of two cycles of injections, on 2-week intervals, of 64 mg of Engensis or placebo in total. Therefore, a total of 192 mg of Engensis was given to each subject over a 4-month period. In addition, there was a follow-up period of 6 months after the first injection on Day 0. The results of the study demonstrated that Engensis was safe and well tolerated at this dosing regimen. There was no difference in the frequency of TEAEs (83% for each group) between the Engensis and the placebo groups. One TEAE, bronchitis, was reported in the Engensis group but was determined to not be related to the study drug. Injection site reactions were reported by 50% of the Engensis group and by 66.7% of the placebo group. Most of the injection site reactions were Grade 1 or 2 and resolved within a short time, and none of the participants in the study discontinued due to the number of injections. These data suggest that high dose, repeated treatments of Engensis, were safe and well tolerated, providing a great deal of flexibility in designing dosing schemes for future clinical studies. Given the primary endpoint of this study was to test safety and tolerability, efficacy was measured only as an exploratory parameter. ALSFRS-R scores, muscle functions using handheld dynamometry, and ALSAQ-40 were among the measurements collected. Since the study size was small and 4 subjects dropped out early, the company were unable to compare efficacy between the Engensis and placebo groups. An important component of this study was the collection of biopsy samples from the participants' injections sites. Engensis is an intramuscularly delivered gene therapy. The bulk of the data collected to date, showing effects of HGF expressed from Engensis, has been from animal models. Data collected from clinical trials has been limited thus far. Thanks to dedicated clinical trial participants, muscle biopsy samples were collected during the course of the trial and will be subjected to histological and molecular biological analyses using RNA-Seq. Helixmith greatly appreciates the generous and eager participation of the ALS patients. Data from these results are expected to provide valuable information on the understanding of the mechanisms of actions of Engensis, and its effects on the expression of human genes, which will greatly help in the development of innovative medicines based on HGF/c-Met signaling. Helixmith will continue the analysis of the Phase 2A data upon the receipt of the full report and plan to present results at a future conference and determine next steps for Engensis in ALS at that time. Aankondiging • Aug 04
Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19 Helixmith announced topline results from the double-blind placebo controlled multicenter study for TADIOS involving one hundred subjects infected with COVID-19. This study was conducted in India in compliance with AYUSH guidelines. TADIOS is Helixmith's proprietary botanical formulation composed of three plants, which has been developed for the treatment of respiratory disease caused by viruses, microdust, and such. The primary goal of this study was to evaluate safety and tolerability of TADIOS, as well as its effects on efficacy parameters, which included biomarkers and clinical symptoms. Subjects diagnosed with COVID-19 infection, showing mild to moderate symptoms, were enrolled according to the clinical management guidelines of the Government of India. Subjects were randomized to TADIOS and placebo with a 1:1 ratio in which fifty patients were assigned in each group. TADIOS and placebo were administered in addition to the standard of care in a double-blinded manner. Efficacy parameters were measured after the 10-day treatment maximum per COVID-19 treatment guideline of India. Safety was assessed at 14-day follow up after treatment was completed. TADIOS was determined to be safe and well tolerated. The TADIOS treated group did not show any difference in adverse events compared to the placebo group, confirming its potential to be developed as a safe botanical treatment for COVID-19 treatment. In terms of efficacy, IL-1RA biomarker showed a statistically significant difference and improvement was demonstrated in one of the fatigue-related questionnaires. IL-1RA levels were higher by more than 3-fold in both groups, but the TADIOS treatment group showed a lower level at 2 weeks after the end of administration, compared to the placebo group (p<0.05). It has been reported that IL-1RA is maintained at elevated levels in blood during COVID-19 infection, and its level has a close correlation with the severity and mortality of infection. While known to regulate excessive inflammation, it is also present at elevated levels in a variety of pathologic conditions, such as obesity and rheumatoid arthritis, as well as at the severe stage of COVID-19 infection. Therefore, reduction of IR-1RA by taking TADIOS suggests its possibility of preventing or inhibiting the progression of symptoms caused by COVID-19 infection to severe illness. Among the six biomarkers measured, serum levels of CRP, ferritin, TNF-a and the level of hemoglobin in whole blood were all within the normal range in both groups. and no difference was shown between the two groups. TADIOS showed some improvement in fatigue, a common symptom in individuals with COVID-19 infections. In one of the questionnaires testing "I am easily fatigued," TADIOS-administered subjects showed statistically significant improvement vs placebo group, two weeks after treatment (p<0.05). Helixmith is planning to present full data at either an academic conference or in a journal publication upon the completion of the analysis. Reported Earnings • May 26
First quarter 2022 earnings released: ₩335 loss per share (vs ₩92.65 profit in 1Q 2021) First quarter 2022 results: ₩335 loss per share (down from ₩92.65 profit in 1Q 2021). Net loss: ₩12.6b (down ₩15.3b from profit in 1Q 2021). Over the next year, revenue is expected to shrink by 16% compared to a 25% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 28
Price target increased to ₩29,182 Up from ₩26,529, the current price target is provided by 1 analyst. New target price is 44% above last closing price of ₩20,200. Stock is down 27% over the past year. The company posted a net loss per share of ₩1,753 last year. Price Target Changed • Apr 27
Price target decreased to ₩26,529 Down from ₩29,182, the current price target is provided by 1 analyst. New target price is 32% above last closing price of ₩20,150. Stock is down 29% over the past year. The company posted a net loss per share of ₩1,753 last year. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Price Target Changed • Dec 29
Price target decreased to ₩26,529 Down from ₩32,100, the current price target is provided by 1 analyst. New target price is 19% above last closing price of ₩22,350. Stock is down 26% over the past year. The company posted a net loss per share of ₩3,094 last year. Aankondiging • Dec 02
Helixmith Announces 50% Enrollment in Clinical Trial for COVID-19, Involving TADIOS Helixmith Co. Ltd. has announced that 50 subjects have been enrolled in its double-blind placebo controlled COVID-19 clinical trial involving 100 subjects. The investigational product is called TADIOS, which is a proprietary botanical treatment. The clinical trial is being conducted in India in accordance with the regulations of the Ministry of AYUSH, India's traditional medicine regulatory body. India has a high rate of COVID-19 infection and unmet medical need. The ongoing TADIOS clinical trial is being conducted in four trial sites. The trial is targeting patients diagnosed with COVID-19 who have mild to moderate clinical symptoms. Patients are being randomized 1:1, 50 subjects to the TADIOS group and 50 to the placebo group. TADIOS is being orally administered as an adjuvant to the COVID-19 standard treatment regimen under double-blinded conditions, and its efficacy and safety are assessed at 10 days and 14 days after administration. Various biochemical indicators, such as TNF-alpha, CRP, IL-6, IL-1Ra, Hb, and ferritin, are being measured at 10 days post administration or at the time of discharge, if earlier than 10 days. Anti-inflammatory and anti-oxidative activities are also being assessed. Clinical symptom improvement is determined using an 8-point sequence scale designed by the WHO. Quality of life, fatigue, and hospitalization periods are also evaluated. In pre-clinical studies, TADIOS (HX110) has shown to significantly inhibit lung damage in an acute lung injury mouse model. The therapeutic effects appeared to result from the control of excessive production of inflammatory and oxidative molecules such as TNF-a, IL-6, IL-1ß and ROS. The potential molecular mechanism underlying TADIOS' anti-inflammatory and anti-oxidative activities is its control of the Nrf2-HO-1 pathway. Thus, TADIOS appears to prevent or inhibit disease progression upon viral infection through a reduction of inflammatory and oxidative response. The results of these studies were published in the Journal of Ethnopharmacology. Price Target Changed • Apr 16
Price target decreased to ₩33,000 Down from ₩48,697, the current price target is provided by 1 analyst. New target price is 29% above last closing price of ₩25,500. Stock is down 62% over the past year. Is New 90 Day High Low • Feb 24
New 90-day low: ₩24,550 The company is down 16% from its price of ₩29,200 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. Aankondiging • Jan 23
Helixmith Co., Ltd announced that it has received KRW 20 billion in funding On January 22, 2021, Helixmith Co., Ltd (KOSDAQ:A084990) closed the transaction. Aankondiging • Jan 22
Helixmith Co., Ltd announced that it expects to receive KRW 20 billion in funding Helixmith Co., Ltd (KOSDAQ:A084990) announced a private placement of 4th series unregistered non-guaranteed private convertible bonds for gross proceeds of KRW 20,000,000,000 on January 20, 2021. The transaction will include participation from new investor, Japan-made New Bio Fund. The bond is issued at 0% coupon rate and will mature on January 22, 2026. The bonds are 100% converted into 657,527 common shares representing 1.92% stake at a fixed conversion price of KRW 30,417 per share. The conversion period is from January 22, 2022 to December 22, 2025. The transaction has been approved by the board of directors of the company. The subscription date is January 20, 2021 and payment date is January 22, 2021. Aankondiging • Dec 23
Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion. Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 7,500,000
Price\Range: KRW 21500
Discount Per Security: KRW 322.5
Transaction Features: Rights Offering Is New 90 Day High Low • Oct 16
New 90-day low: ₩30,750 The company is down 48% from its price of ₩58,800 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. Aankondiging • Oct 06
Helixmith to Be Deleted from Other OTC Helixmith Co., Ltd’s Ordinary Shares will be deleted from Other OTC effective September 29, 2020. The deletion is due to Inactive Security. Is New 90 Day High Low • Sep 18
New 90-day low: ₩41,800 The company is down 35% from its price of ₩64,500 on 19 June 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period. 
